Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer : The ORIENT-16 Randomized Clinical Trial
Importance: Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death 1 (PD-1), in combination with chemotherapy, has demonstrated promising efficacy.
Objective: To compare overall survival of patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancers who were treated with sintilimab with chemotherapy vs placebo with chemotherapy. Also compared were a subset of patients with a PD ligand 1 (PD-L1) combined positive score (CPS) of 5 or more (range, 1-100).
Design, Setting, and Participants: Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 62 hospitals in China that enrolled 650 patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma between January 3, 2019, and August 5, 2020. Final follow-up occurred on June 20, 2021.
Interventions: Patients were randomized 1:1 to either sintilimab (n = 327) or placebo (n = 323) combined with capecitabine and oxaliplatin (the XELOX regimen) every 3 weeks for a maximum of 6 cycles. Maintenance therapy with sintilimab or placebo plus capecitabine continued for up to 2 years.
Main Outcomes and Measures: The primary end point was overall survival time from randomization.
Results: Of the 650 patients (mean age, 59 years; 483 [74.3%] men), 327 were randomized to sintilimab plus chemotherapy and 323 to placebo plus chemotherapy. Among the randomized patients, 397 (61.1%) had tumors with a PD-L1 CPS of 5 or more; 563 (86.6%) discontinued study treatment and 388 (59.7%) died; 1 patient (<0.1%) was lost to follow-up. Among all randomized patients, sintilimab improved overall survival compared with placebo (median, 15.2 vs 12.3 months; stratified hazard ratio [HR], 0.77 [95% CI, 0.63-0.94]; P = .009). Among patients with a CPS of 5 or more, sintilimab improved overall survival compared with placebo (median, 18.4 vs 12.9 months; HR, 0.66 [95% CI, 0.50-0.86]; P = .002). The most common grade 3 or higher treatment-related adverse events were decreased platelet count (sintilimab, 24.7% vs placebo, 21.3%), decreased neutrophil count (sintilimab, 20.1% vs placebo, 18.8%), and anemia (sintilimab, 12.5% vs placebo, 8.8%).
Conclusions and Relevance: Among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma treated with first-line chemotherapy, sintilimab significantly improved overall survival for all patients and for patients with a CPS of 5 or more compared with placebo.
Trial Registration: ClinicalTrials.gov Identifier: NCT03745170.
| Errataetall: |
CommentIn: JAMA. 2024 Apr 16;331(15):1333-1334. - PMID 38512227 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:330 |
|---|---|
| Enthalten in: |
JAMA - 330(2023), 21 vom: 05. Dez., Seite 2064-2074 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Jianming [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.12.2023 Date Revised 19.04.2024 published: Print ClinicalTrials.gov: NCT03745170 CommentIn: JAMA. 2024 Apr 16;331(15):1333-1334. - PMID 38512227 Citation Status MEDLINE |
|---|
| doi: |
10.1001/jama.2023.19918 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365422746 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365422746 | ||
| 003 | DE-627 | ||
| 005 | 20240419232148.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jama.2023.19918 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1380.xml |
| 035 | |a (DE-627)NLM365422746 | ||
| 035 | |a (NLM)38051328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Jianming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer |b The ORIENT-16 Randomized Clinical Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2023 | ||
| 500 | |a Date Revised 19.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03745170 | ||
| 500 | |a CommentIn: JAMA. 2024 Apr 16;331(15):1333-1334. - PMID 38512227 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Importance: Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death 1 (PD-1), in combination with chemotherapy, has demonstrated promising efficacy | ||
| 520 | |a Objective: To compare overall survival of patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancers who were treated with sintilimab with chemotherapy vs placebo with chemotherapy. Also compared were a subset of patients with a PD ligand 1 (PD-L1) combined positive score (CPS) of 5 or more (range, 1-100) | ||
| 520 | |a Design, Setting, and Participants: Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 62 hospitals in China that enrolled 650 patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma between January 3, 2019, and August 5, 2020. Final follow-up occurred on June 20, 2021 | ||
| 520 | |a Interventions: Patients were randomized 1:1 to either sintilimab (n = 327) or placebo (n = 323) combined with capecitabine and oxaliplatin (the XELOX regimen) every 3 weeks for a maximum of 6 cycles. Maintenance therapy with sintilimab or placebo plus capecitabine continued for up to 2 years | ||
| 520 | |a Main Outcomes and Measures: The primary end point was overall survival time from randomization | ||
| 520 | |a Results: Of the 650 patients (mean age, 59 years; 483 [74.3%] men), 327 were randomized to sintilimab plus chemotherapy and 323 to placebo plus chemotherapy. Among the randomized patients, 397 (61.1%) had tumors with a PD-L1 CPS of 5 or more; 563 (86.6%) discontinued study treatment and 388 (59.7%) died; 1 patient (<0.1%) was lost to follow-up. Among all randomized patients, sintilimab improved overall survival compared with placebo (median, 15.2 vs 12.3 months; stratified hazard ratio [HR], 0.77 [95% CI, 0.63-0.94]; P = .009). Among patients with a CPS of 5 or more, sintilimab improved overall survival compared with placebo (median, 18.4 vs 12.9 months; HR, 0.66 [95% CI, 0.50-0.86]; P = .002). The most common grade 3 or higher treatment-related adverse events were decreased platelet count (sintilimab, 24.7% vs placebo, 21.3%), decreased neutrophil count (sintilimab, 20.1% vs placebo, 18.8%), and anemia (sintilimab, 12.5% vs placebo, 8.8%) | ||
| 520 | |a Conclusions and Relevance: Among patients with unresectable locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma treated with first-line chemotherapy, sintilimab significantly improved overall survival for all patients and for patients with a CPS of 5 or more compared with placebo | ||
| 520 | |a Trial Registration: ClinicalTrials.gov Identifier: NCT03745170 | ||
| 650 | 4 | |a Clinical Trial, Phase III | |
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Capecitabine |2 NLM | |
| 650 | 7 | |a 6804DJ8Z9U |2 NLM | |
| 650 | 7 | |a sintilimab |2 NLM | |
| 650 | 7 | |a 8FU7FQ8UPK |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a PDCD1 protein, human |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 650 | 7 | |a Programmed Cell Death 1 Receptor |2 NLM | |
| 650 | 7 | |a Oxaloacetates |2 NLM | |
| 700 | 1 | |a Jiang, Haiping |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Yueyin |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Kangsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Cang, Shundong |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Yongqian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jiayi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Junhui |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Hongming |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Suxia |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Yanru |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Qunyi |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Yuxian |e verfasserin |4 aut | |
| 700 | 1 | |a Ling, Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jianwei |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Zhilong |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a He, Yifu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Liangming |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Xinjun |e verfasserin |4 aut | |
| 700 | 1 | |a Niu, Zuoxing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jingdong |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Yingmei |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ziran |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Hui |e verfasserin |4 aut | |
| 700 | 0 | |a ORIENT-16 Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Hongmei |e investigator |4 oth | |
| 700 | 1 | |a Wang, Qi |e investigator |4 oth | |
| 700 | 1 | |a Li, Junhe |e investigator |4 oth | |
| 700 | 1 | |a Jiang, Da |e investigator |4 oth | |
| 700 | 1 | |a Guo, Weijian |e investigator |4 oth | |
| 700 | 1 | |a Ying, Jieer |e investigator |4 oth | |
| 700 | 1 | |a Wang, Shubin |e investigator |4 oth | |
| 700 | 1 | |a Zang, Aimin |e investigator |4 oth | |
| 700 | 1 | |a Cai, Shirong |e investigator |4 oth | |
| 700 | 1 | |a Hu, Chunhong |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Tao |e investigator |4 oth | |
| 700 | 1 | |a Tao, Min |e investigator |4 oth | |
| 700 | 1 | |a Liang, Jun |e investigator |4 oth | |
| 700 | 1 | |a Mao, Qinsheng |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Minghui |e investigator |4 oth | |
| 700 | 1 | |a Mao, Rui |e investigator |4 oth | |
| 700 | 1 | |a Yang, Hui |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Hongyu |e investigator |4 oth | |
| 700 | 1 | |a Shen, Lin |e investigator |4 oth | |
| 700 | 1 | |a Lu, Jin |e investigator |4 oth | |
| 700 | 1 | |a Li, Wenxin |e investigator |4 oth | |
| 700 | 1 | |a Chen, Yamin |e investigator |4 oth | |
| 700 | 1 | |a Chen, Lei |e investigator |4 oth | |
| 700 | 1 | |a Zhuang, Zhixiang |e investigator |4 oth | |
| 700 | 1 | |a Bai, Chunmei |e investigator |4 oth | |
| 700 | 1 | |a Liu, Heli |e investigator |4 oth | |
| 700 | 1 | |a Chen, Jingtang |e investigator |4 oth | |
| 700 | 1 | |a Liao, Wangjun |e investigator |4 oth | |
| 700 | 1 | |a Qiu, Meng |e investigator |4 oth | |
| 700 | 1 | |a Song, Rongfeng |e investigator |4 oth | |
| 700 | 1 | |a Li, Man |e investigator |4 oth | |
| 700 | 1 | |a Qian, Suying |e investigator |4 oth | |
| 700 | 1 | |a Liu, Yunpeng |e investigator |4 oth | |
| 700 | 1 | |a Liu, Jiang |e investigator |4 oth | |
| 700 | 1 | |a Wang, Dong |e investigator |4 oth | |
| 700 | 1 | |a Yin, Xianli |e investigator |4 oth | |
| 700 | 1 | |a Huang, Zhiming |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA |d 1948 |g 330(2023), 21 vom: 05. Dez., Seite 2064-2074 |w (DE-627)NLM000006939 |x 1538-3598 |7 nnns |
| 773 | 1 | 8 | |g volume:330 |g year:2023 |g number:21 |g day:05 |g month:12 |g pages:2064-2074 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1001/jama.2023.19918 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 330 |j 2023 |e 21 |b 05 |c 12 |h 2064-2074 | ||